

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-.

Bacterial Pneumonia

Saud Bin Abdul Sattar; Andrew D. Nguyen; Sandeep Sharma.

► Author Information and Affiliations

Last Update: February 26, 2024.

Continuing Education Activity

Bacterial pneumonia, characterized by inflammation in lung parenchyma and alveolar spaces, is caused by various bacteria, each triggering an intricate interplay with the host immune response. Clinically, patients may experience symptoms such as fever, cough, dyspnea, and chest pain, with potential complications ranging from necrotizing pneumonia and empyema to meningitis, sepsis, and multiple organ failure. Long-term impacts on pulmonary function and quality of life can ensue.

This activity enhances knowledge of the disease's impact on pulmonary function and quality of life, recognizing the potential long-term consequences for patients. The focus on a multidisciplinary approach underscores the importance of collaboration among healthcare professionals in managing bacterial pneumonia. Clinicians will learn practical strategies for history-taking and physical examination to identify exposures and risk factors, enabling targeted and personalized patient management. Additionally, the activity provides insights into vaccination strategies, early mobilization, and rehabilitation, offering a holistic view of patient care. Overall, participation in this activity equips clinicians with the knowledge and skills needed to navigate the complexities of bacterial pneumonia and deliver optimal care within an interprofessional healthcare team.

Objectives:

- Identify the clinical manifestations and history features indicative of bacterial pneumonia to facilitate timely diagnosis.
- Select appropriate diagnostic tests, considering their sensitivity and specificity, to enhance diagnostic accuracy and guide effective therapeutic interventions.
- Implement evidence-based antimicrobial management strategies based on local epidemiology, susceptibility testing, and patient-specific factors to optimize treatment outcomes.
- Coordinate with various healthcare professionals to implement a cohesive and patient-centered approach to enhance the overall quality of care for individuals affected by bacterial pneumonia.

[Access free multiple choice questions on this topic.](#)

Introduction

Bacterial pneumonia, characterized by inflammation in lung parenchyma and alveolar spaces, is caused by various bacteria, each triggering an intricate interplay with the host immune response. Clinically, patients may experience symptoms such as fever, cough, dyspnea, and chest pain, with potential complications ranging from necrotizing pneumonia and empyema to meningitis, sepsis, and multiple organ failure. Long-term impacts on pulmonary function and quality of life can ensue.

The word pneumonia is rooted in the ancient Greek word *pneumon* ("lung"). Therefore, pneumonia can be understood as "lung disease." [1] Clinically, it manifests as an inflammation of the parenchyma and alveolar spaces in 1 or both lungs, primarily attributed to infections, though not exclusively. [2]

Among the infectious causes of pneumonia, bacteria, viruses, fungi, and parasites are prominent. Bacterial pneumonia has a significant impact on the overall morbidity and mortality rates of those with pneumonia. [3][4] Various classification methods exist for organizing pneumonia, with the National Institutes of Health (NIH) system being the most widely embraced. This system categorizes pneumonia into community-acquired, hospital-acquired, and atypical pneumonia, further stratified based on severity. [5][6]

Additional classifications may include healthcare-acquired pneumonia (HCAP), which encompasses pneumonia acquired in hospitals, dialysis units, residential aged facilities, and ventilator-associated pneumonia (VAP). [2][7] However, HCAP has been omitted from American guidelines due to a lack of evidence regarding microbiological differences between community-acquired pneumonia (CAP) and HCAP. [8]

Bacterial Pneumonia Definitions

- **Community-acquired pneumonia:** CAP is the acute infection of lung tissue occurring in a patient who has acquired it from the community or within 48 hours of hospital admission.
- **Hospital-acquired pneumonia:** HAP is an acute infection of lung tissue in a nonintubated patient that develops after 48 hours of hospitalization.
- **Atypical pneumonia:** The acute infection caused by a pathogen not detectable by traditional Gram stain or standard cultures.
- **Ventilator-associated pneumonia:** VAP is a type of nosocomial infection of lung tissue that usually develops 48 hours or longer after intubation for mechanical ventilation.

Etiology

CAP can result from an extensive list of agents, including bacteria, viruses, fungi, and parasites. However, this activity will specifically concentrate on bacterial pneumonia and its causative factors. Bacteria have traditionally been classified into 2 categories based on etiology: typical and atypical organisms. Typical organisms can be cultured on standard media or identified through Gram stain, whereas atypical organisms lack such properties. [6]

- Typical pneumonia refers to pneumonia primarily caused by *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, Group A *Streptococci*, *Moraxella catarrhalis*, anaerobes (often secondary to aspiration or oropharyngeal contents), and other aerobic Gram-negative bacteria.
- *Legionella* species, *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*, and *Chlamydia psittaci* predominantly cause atypical pneumonia.
- Opportunistic infections can include organisms such as *Mycobacterium tuberculosis* and *Nocardia* species.

The primary cause of CAP globally is *S pneumoniae*, a trend observed in adults and children. [9][10][11][12] *H influenzae* is frequently cited as the second most prevalent bacterial pathogen. However, the prevalence of other commonly isolated pathogens can vary depending on the geographical location and local epidemiology. These may include *Klebsiella pneumoniae*, *Legionella* species, *M pneumoniae*, *Chlamydia* species, *Pseudomonas aeruginosa*, and in some

areas of the world, *Mycobacterium tuberculosis* and *Burkholderia pseudomallei*.

[13] *Escherichia coli*, *Proteus mirabilis*, and other gram-negative coliform bacteria may be associated with aspiration events.[14] *Bordetella pertussis* may be relevant in unvaccinated populations.

Bacterial pathogens in HAP and HCAP globally include *K pneumoniae*, *E coli*, *P aeruginosa*, *S aureus*, including methicillin-resistant *S aureus* (MRSA), *Enterobacter* species, and *Acinetobacter baumannii* complex.[15][16] Many of these pathogens are also causative agents of VAP, encompassing non-multidrug-resistant (MDR) agents (eg, *S pneumoniae*, other *Streptococcus* species, *H influenzae*) and MDR (eg, *P aeruginosa*, MRSA, *A baumannii* complex and antibiotic-resistant *Enterobacteriaceae*) bacterial pathogens.[17][18]

Epidemiology

Globally, the annual incidence of CAP reaches up to 450 million cases, with approximately 95% occurring in developing countries, contributing to around 4 million deaths annually.[19] In Europe, the incidence varies from 206 to 470 cases per 100,000 patients per year.[20][21] while in China, reported incidence ranges from 298 to 2210 cases per 100 patient-years.[22] In the United States, lower respiratory tract infections surpass all other infections in terms of morbidity and mortality, with approximately 649 to 847 CAP cases per 100,000 patient years being hospitalized, disproportionately affecting low-income and minority groups.[23][24][25][26]

An elevated incidence of CAP is observed in specific age groups, specifically those younger than 4 years and 65 or older.[27][28] In the US, there are an estimated 2.2 to 8 million hospitalized cases annually, though other estimates suggest an annual incidence of 5 million or more CAP cases.[28] Stratified by bacterial predominance, the estimated annual frequency of *M pneumoniae*, *C pneumoniae*, and *Legionella* species cases in the US is estimated at 108,000, 49,700, and 18,000, respectively.[28]

Approximately 100,000 cases of CAP-related deaths occur annually in the US, with global mortality rates ranging from 2.6% to 18.5% at the time of hospitalization and up to 31% to 44.5% within a year of hospitalization.[29][30][31] Admission to the intensive care unit (ICU) is associated with increased mortality risk in CAP.[32] Despite the severity of the condition, up to 90% of CAP cases are successfully managed in the outpatient setting. Hospitalization is typically prompted by comorbidities and the progression of CAP, with a low mortality rate of 0.1% for outpatient-managed cases.[29][33]

Pathophysiology

The lower respiratory tract is not a sterile environment and is constantly exposed to environmental pathogens. Invasion and propagation of bacteria into lung parenchyma at the alveolar level can cause bacterial pneumonia. The body's inflammatory response against this invasion leads to the clinical symptoms of pneumonia.[34]

Various host defenses collaborate in the lungs to prevent microorganism proliferation. Mechanical defenses, such as nasal hair and mucus, and chemical defenses, including alveolar epithelial cell-produced proteins like surfactant proteins A and D with inherent opsonizing properties, contribute.[35] The early innate immune response involves neutrophilic infiltration triggered by toll-like receptor recognition.[36] Activated alveolar macrophages work to engulf and eliminate bacteria. However, if bacterial growth exceeds host defense capacity, their numbers rise.

Pathogenic bacteria have various virulence factors that facilitate the evading host immune responses. Examples include polysaccharide capsules in *S pneumoniae*, adhesion proteins in *M pneumoniae*, and pili associated with biofilm formation in *Legionella pneumophila*. [37][38][39] [40]

Alveolar macrophages initiate host inflammatory responses upon bacterial invasion to limit bacterial spread within the human host. The host inflammatory responses are the primary drivers of the clinical manifestations observed in bacterial pneumonia. Cytokines are released in response to the inflammatory reaction, initiating a cascade that manifests as constitutional symptoms. For instance, interleukin-1 (IL-1) and tumor necrosis factor (TNF) are associated with fever, commonly observed in bacterial pneumonia.[34]

Chemokine-like interleukin-8 (IL-8) and colony-stimulating factors like granulocyte colony-stimulating factor (G-CSF) promote chemotaxis and neutrophil maturation, leading to leukocytosis. Other cytokines, such as interleukin-9 (IL-9) and interleukin-13 (IL-13), promote mucin production, forming purulent secretions that aid in bacterial inactivation. [41] These proinflammatory cytokines are responsible for the leakage of the alveolar-capillary membrane at the inflammation site, facilitating the migration of host leukocytes to the site of bacterial burden in the lungs. This leakage can result in decreased gas exchange and associated fibrosis, causing reduced compliance and manifesting as progressive and severe dyspnea.[42]

Inflammation within the pleura can trigger somatic receptors of the phrenic nerve within the parietal pleura, causing pleuritic chest pain.[43] Localized necrosis from damage to the lung parenchyma and tissue extravasation can result in hemoptysis.[44]

Histopathology

Pathologically, lobar pneumonia is characterized by the acute exudative inflammation of a lung lobe. If left untreated, it progresses through the following 4 advanced stages, which may overlap with one another:

1. **Congestion:** Pulmonary parenchyma is not fully consolidated, and microscopically, the alveoli contain serous exudates, including pathogens, some neutrophils, and macrophages.
2. **Red hepatization:** The affected lobe consolidates, acquiring a firm and liver-like texture. Microscopically, there is evidence of fibrin, serous exudate, pathogens, neutrophils, and macrophages. Capillaries are congested, and alveolar walls are thickened.
3. **Gray hepatization:** The lobe maintains a liver-like consistency but appears gray due to supportive and exudate-filled alveoli. This stage can be further subdivided based on the proportion of fibrin to leukocytes.
4. **Resolution:** Typically occurring after a week, this stage involves resolving the inflammatory process. Lymphatic drainage or a productive cough aids in clearing the exudate.[45]

History and Physical

When obtaining a patient's history, it is crucial to thoroughly investigate potential exposures, risks of aspiration, host factors, and presenting symptoms. Various comorbidities, such as cardiopulmonary conditions, neurological impairment, HIV, renal and liver disease, age, sex, smoking, alcohol misuse, and poor dental hygiene, can impact the risk for bacterial pneumonia, particularly CAP.[46][47] Assessing vaccination history becomes pertinent, particularly for infections caused by *H influenzae* and *B pertussis*. [48] Additionally, intravenous drug use can be a risk factor for bacterial pneumonia, including *S aureus* pneumonia.[49] In any patient presenting with suspected bacterial pneumonia, it is essential to consider and evaluate all these potential risk factors.

Exposure

A comprehensive history of potential exposures is essential, as it aids in establishing possible etiologies. The following associations highlight specific exposures and their corresponding etiologies in bacterial pneumonia:

- *Legionella pneumonia*:
 - Associations: Smoking, contaminated air-conditioning, and water systems, such as in cruise ships and hotels [50][51][52]
- Pneumonia in crowded spaces:
 - Associations: Jails and shelters
 - Etiologies: *S pneumoniae*, *Mycobacteria* species, *M pneumoniae*, and *C pneumonia* [53][54][55][56]
 - Association
- Psittacosis:
 - Associations: Exposure to some birds, such as chickens, turkeys, and ducks
 - Etiology: *C psittaci* [57]
- Tularemia:
 - Associations: Exposure to infected rabbits, possums, arthropods, and rodents
 - Etiology: *Francisella tularensis* [58][59]
- Leptospirosis and plague:
 - Associations: Exposure to infected rodents.
 - Etiologies: *Leptospira* species, *Yersinia pestis* [58][60][61]
- Q fever:
 - Associations: Exposure to macropods, cats, sheep, and cattle
 - Etiology: *Coxiella burnetii* [62][63]
- Melioidosis:
 - Associations: Inhalational proximity to disrupted soils in endemic areas.
 - Etiology: *B pseudomallei* [64]
- Immunocompromised pneumonia:
 - Etiologies: Hospitalization, corticosteroid or cytotoxic therapy, neutropenia
 - Etiology: *P aeruginosa* [65]

Risks of Aspiration

Patients with an increased aspiration risk are more susceptible to developing pneumonia secondary to aspiration. Associated risks include the following:[66][67][68]

- Altered mentation (including dementia, alcoholism, seizure disorders, and psychotropic drug use)
- Polypharmacy
- Dysphagia
- Gastroesophageal reflux disease (GERD)
- Daily supplemental oxygen therapy

- Dependency on oral care
- Decayed dentition
- Iatrogenic feeding supports dependency
- Sputum suctioning
- Smoking
- Urinary catheterization

Host Mechanisms

Obtaining a detailed history is of utmost importance to uncover clues to the etiology of pneumonia. For instance, a history of asthma, chronic obstructive pulmonary disease (COPD), smoking, and immunocompromised status can be indicative of *H influenzae* infection,[69] [70] which most commonly appears in the winter season. Similarly, social, sexual, medication, and family history can all help determine the cause of illness. For example, a history of advanced HIV with CD4 counts less than 100 cells/mm³ can predispose to increased rates of bacterial pneumonia and opportunistic infections, including pulmonary tuberculosis and pulmonary cryptococcosis.[71]

Physical Manifestations

Features in the history of bacterial pneumonia may vary from indolent to fulminant. Clinical manifestations encompass constitutional findings and those resulting from lung and related tissue damage.[34] The following are significant findings obtained on a history:[72]

- Fever with tachycardia or chills and sweats
- Cough may be nonproductive or productive, with mucoid, purulent, or blood-tinged sputum
- Pleuritic chest pain if the pleura is involved
- Shortness of breath with normal daily routine work
- Fatigue, headache, myalgia, and arthralgia

A productive cough is the most common and significant presenting symptom. Some bacterial causes have historically been associated with particular sputum characteristics, such as:

- *S pneumoniae*: Rust-colored [73]
- *Pseudomonas*, *Hemophilus* species: Green [74]
- *K pneumoniae*: Red currant-jelly [75]
- Anaerobes: foul-smelling and bad-tasting [76]

More recent pooled analyses of randomized trials demonstrate that sputum color is not specific to one organism and may not correlate with culturable bacterial pathogens in up to 55% of cases. [74].

Atypical pneumonia presents with pulmonary and extrapulmonary manifestations. For instance, *Legionella* pneumonia often presents with altered mentation (including encephalitis, meningitis, and peripheral neuropathy), myocarditis, panniculitis, myositis, and cutaneous symptoms.[77][78]

Physical findings in bacterial pneumonia can vary among patients and are primarily influenced by the severity of lung consolidation, the type of organism, the extent of the infection, host

factors, and the presence or absence of pleural effusion. The following are major clinical findings:[79][80][81][82]

- Fever ($>38^{\circ}\text{C}$ or 100.4°F)
- Hypothermia ($<35^{\circ}\text{C}$ or 95°F)
- Tachypnea (>18 breaths/min)
- Tachycardia (>100 bpm)
- Bradycardia (<60 bpm)
- Cyanosis
- Decreased chest expansion on the affected side
- Tracheal deviation in severe cases
- Percussion sounds vary from flat to dull
- Tactile fremitus
- Crackles, rales, and bronchial breath sounds are heard during auscultation
- Increased vocal resonance over the site of lobar consolidation
- Whispering pectoriloquy
- Lymphadenopathy
- Pleural rub
- Egophony (E to A changes)
- Hypoxia on pulse oximetry, which may be related to intrapulmonary shunting from perfused but poorly ventilated alveoli

Clinical findings that may be observed in infants include tachypnea, nasal flaring, intercostal retraction, abdominal distension, decreased feeding, and lethargy.[83] In children younger than 5 years, presentations may include tachypnea, chest indrawing, chest pain, abdominal pain, or pallor if unwell.[84] Children may not always exhibit typical examination findings consistent with pneumonia, necessitating a low threshold for chest radiography when history and examination alone cannot confirm pneumonia.[85]

In older patients, confusion may manifest earlier, and features such as fevers, rigors, and sputum production may not be as pronounced as in younger adults.[86] A critically ill patient may present with sepsis or multiple organ failure.[87]

Examination findings may be specific for certain etiologies, as outlined below:

- Relative bradycardia: *Legionella* species [88]
- Dental illnesses: Anaerobes [89]
- Impaired gag reflex and dysphagia: Aspiration pneumonia [67]
- Cutaneous nodules: Nocardiosis [90]
- Bullous myringitis: *Mycoplasma* species [91]
- Scrofula and spinal deformity: Tuberculosis [92][93]
- Osteomyelitis and lower lobe pneumonia: Actinomycosis [94][95]

Evaluation

The approach to evaluating and diagnosing pneumonia depends on the clinical status, laboratory parameters, and radiological evaluation.

Clinical Evaluation

The clinical evaluation involves a comprehensive patient history and a thorough physical examination to assess the clinical signs and symptoms mentioned previously. Prognostic scoring systems, such as the CURB-65, CORB (confusion [acute], oxygen saturation $\leq 90\%$, respiratory rate ≥ 30 breaths/min, and blood pressure < 90 mm Hg [systolic] or ≤ 60 mm Hg [diastolic]), SMART-COP (systolic blood pressure, multilobar infiltrates, albumin, respiratory rate, tachycardia, confusion, oxygen, and pH), and the Pneumonia Severity Index (PSI) may be used as adequate predictors of medical complications such as ICU admission and death; however, prediction rules are often not robust enough to replace clinical judgment at the time of assessment.[32][96][97]

Illustratively, the CURB-65 score comprises:

- C = Confusion
- U = Uremia (BUN > 20 mg/dL)
- R = Respiratory rate (> 30 breaths/min)
- B = BP (BP $< 90/60$ mm Hg)
- Age older than 65 years

A score of 0 to 1 advises outpatient treatment, 2 or greater suggests medical admission, and 3 or greater indicates ICU admission.[98]

Laboratory Evaluation

In the diagnostic process for pneumonia, laboratory values play a crucial role. This includes assessing a complete blood count (CBC) with differentials, inflammatory biomarkers like erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), blood cultures, sputum analysis or Gram staining and possibly urine antigen testing, or polymerase chain reaction (PCR) for nucleic acid detection of certain bacteria.[99][100][101]

Arterial blood gas analysis can reveal hypoxia and respiratory acidosis. Severe hypoxia is indicated by pulse oximetry readings of less than 92%, and an elevated CRP level predicts a severe infection.[102]

Obtaining blood cultures before administering antibiotics is recommended in high-severity cases.[103] However, they are positive in less than 10% of cases and may provide minimal clinical benefit in mild to moderate CAP.[104]

Good quality sputum evaluation may reveal more than 25 white blood cells (WBC) per low-power field and fewer than 10 squamous epithelial cells, allowing for visualization of bacteria through Gram stain techniques.[105][106] Microbiology tests can be performed to differentiate between similar microorganisms, such as distinguishing between *Nocardia* species and other anaerobic *Actinomyces* or between *Nocardia* species and the more acid-fast *M tuberculosis*. [107] [108] *S pneumoniae* can be differentiated from other Gram-positive cocci through optochin susceptibility and latex agglutination.[109][110] *Legionella* species can be differentiated from other pulmonary pathogens, except *Nocardia* and *Francisella* species, as it can be grown only buffered with charcoal yeast extraction.[111][112]

Antimicrobial susceptibility testing is crucial for targeting appropriate antibiotic treatment for bacterial pneumonia.[113] Additionally, it helps guide clinicians in adjusting treatment regimens

based on the specific resistance patterns of the identified bacterial pathogens, ensuring optimal therapeutic outcomes for patients with bacterial pneumonia.

Specific biochemical evidence may also be present in some bacterial causes. For instance, *Legionella* may be associated with hyponatremia and microhematuria.[114][115] Recognizing these specific biochemical markers aids in the early identification and targeted management of bacterial infections, contributing to a more comprehensive understanding of the underlying etiology and facilitating prompt and effective therapeutic interventions.

Radiological Evaluation

Diagnostic imaging is pivotal in pneumonia evaluation, with a chest X-ray as an initial imaging test. Pulmonary infiltrates identified on plain film are considered a gold standard for diagnosis when supported by laboratory and clinical features.[3][116] The chest X-ray may uncover consolidations or parapneumonic effusions. *S aureus* pneumonia may manifest with multilobar involvement, patchy opacities, and cavitary lesions indicative of abscess formation.[117]

Transthoracic and transesophageal echocardiograms exclude endocarditis in cases of *S aureus* pneumonia with bacteremia.[118] Early identification of endocarditis through echocardiograms allows for prompt intervention and tailored treatment strategies, improving patient outcomes in *S aureus* pneumonia with bacteremia cases.

H influenzae infections are more likely to exhibit bronchopneumonia changes on chest radiography.[119] *P aeruginosa* manifestations include patchy opacities with abscess formation, a pattern also observed in *B pseudomallei* pneumonia.[120] A "bulging fissure" sign associated with pulmonary abscesses may be evident in *K pneumoniae*. However, it is also observed in *S pneumoniae*, *H influenzae*, *M tuberculosis*, and *Y pestis* pulmonary infections.[121][122]

Chest CT is reserved for complex cases with an unknown cause or those with structural lung disease.[123] Bronchoalveolar lavage is conducted in intubated patients, providing culture samples for further analysis.[124]

Treatment / Management

Once a pneumonia diagnosis is confirmed, the initial step in treatment involves a risk assessment to determine whether the patient should receive outpatient or inpatient care.[3][125][126]. In all cases of severe bacterial pneumonia, immediate initiation of empirical therapy is crucial to prevent sepsis, a common cause of ICU admission and mortality.[127]

While various scoring calculators can be used to risk stratify patients, clinical judgment remains essential in their application. The choice of empirical antibiotics depends on local epidemiology and the prevalent bacterial pathogens in the region.[3][128][129][130] Options may include benzylpenicillin or third-generation cephalosporins for *S pneumoniae*, macrolides for *Legionella* species, and carbapenems or ceftazidime for *B pseudomallei*, varying by geographic location.

For administration, benzylpenicillin powder is reconstituted with water for injection, while ceftriaxone is mixed with 10 mL water for intravenous and intramuscular administration, often combined with lignocaine.[131] Respiratory fluoroquinolones or a combination of beta-lactam antibiotics with macrolides are recommended as first-line treatments in the US.[132]

Rationalizing antimicrobial therapy is advised when susceptibility testing results are available. For *P aeruginosa*-related pneumonia with sepsis, piperacillin and tazobactam may be used, and depending on resistance profiles, other options include ceftazidime, ceftazidime/avibactam (for difficult-to-treat *Pseudomonas*), cefepime, ciprofloxacin, and meropenem [133].

For outpatient management of patients lacking comorbidities, suitable antimicrobial options encompass those from penicillin, macrolide, and tetracycline classes. Patients with comorbidities may benefit from a respiratory fluoroquinolone or a combination of amoxicillin/clavulanate with a macrolide.[132] In cases requiring inpatient care, obtaining a microbiological specimen, such as sputum or blood cultures for severe cases, is advised to guide antimicrobial management. However, outpatient cases may not necessitate culture and susceptibility testing. The use of antipyretics is recommended to alleviate symptoms and reduce fevers in affected patients [134].

Following a positive culture result, treatment should be adjusted on the susceptibility results of the culture-specific pathogen. In cases of severe bacterial pneumonia, combination therapy may enhance survival, particularly in CAP patients with associated shock.[135] Patients with bacterial pneumonia without complications or underlying chronic respiratory illness, such as bronchiectasis, may be successfully treated with total antimicrobial durations as short as 5 days, aligning with guidelines established by the Infectious Diseases Society of America and the American Thoracic Society.[136]

The use of corticosteroids in bacterial pneumonia remains controversial and may be considered in patients experiencing persistent hypotension with presumed adrenal insufficiency.[137][138][139][140] Increasing evidence suggests the potential utility of corticosteroids in the intensive care population, showing benefits in preventing progression to mechanical ventilation and reducing mortality by 28 days when administered within 24 hours of severe CAP development. [141][142] The role of noninvasive ventilation is debated in bacterial pneumonia without respiratory failure cases, given high treatment failure rates, with consideration primarily given to those with preexisting COPD.[143] Bronchodilator therapy, without corticosteroid use, may offer limited benefit in moderate to severe exacerbations of COPD with pneumonia.[144]

In addition to pharmacological intervention, nonpharmacological management of bacterial pneumonia includes promoting smoking cessation, providing counseling support, and ensuring vaccination against influenza, COVID-19, and pneumococcus.[145][146][147][148] Encouraging the treatment and correction of dysphagia and addressing any intervening comorbidities are also crucial components of comprehensive patient care.[149]

Home-based treatment patients should be scheduled for a follow-up visit within 2 to 3 days to evaluate the potential development of pneumonia-related complications.[150] For patients discharged following hospitalization for bacterial pneumonia, a follow-up assessment within 7 days is recommended to determine the need for continued antibiotic management or potential rehydration.[151]

The evidence for chest physiotherapy in pneumonia is less clear than its effectiveness in bronchiectasis exacerbations. However, some evidence suggests it may reduce hospitalization duration and the need for mechanical ventilation.[152] As a result, various national guidelines have not recommended traditional airway clearance methods.[153] Instead, patients with pneumonia are encouraged to sit out of bed for at least 20 minutes within the first 24 hours of hospitalization and increase mobility each subsequent day, with consideration for the use of positive expiratory pressure. Lateral decubitus positioning towards the lung affected by consolidation may alleviate symptom burden in bacterial pneumonia with respiratory failure. [154] Prone and upright positioning may play a role in reducing the incidence of VAP.[155][156]

Other measures demonstrated to be effective in bacterial pneumonia include:

- Hydration [152]
- Monitoring with pulse oximetry [157]
- Mechanical support if patients are in acute respiratory distress [158]
- Nutrition [159]

- Early mobilization [153]

Differential Diagnosis

Distinguishing pneumonia from other pulmonary diseases can be challenging, particularly in patients with coexisting pulmonary pathology. The differential diagnoses vary for children and adults:

Differential Diagnosis in Children

- Asthma or reactive airway disease exacerbation
- Bronchiolitis
- Croup
- Respiratory distress syndrome
- Epiglottitis

Differential Diagnosis in Adults

- Acute and chronic bronchitis
- Acute pulmonary edema
- Acute respiratory distress syndrome
- Aspiration of a foreign body
- Asthma exacerbation
- Atelectasis
- Bronchiectasis
- Bronchiolitis
- Chronic obstructive pulmonary disease exacerbation
- Fungal pulmonary infection (including *Pneumocystis jiroveci* pneumonia)
- Interstitial lung disease
- Lung abscess
- Organizing pneumonia
- Respiratory failure
- Viral pulmonary infection

Prognosis

The prognosis of pneumonia is influenced by various factors, including age, cognitive status, comorbidities (including malignancy and chronic respiratory diseases), immunosuppression, chronic alcohol misuse, hospital setting (inpatient or outpatient), and the need for ventilatory support.[160] The prognosis and survival for bacterial pneumonia are generally more favorable in otherwise healthy patients.[161]

Older patient groups tend to experience poorer clinical outcomes than their younger counterparts.[162] An observational study noted higher mortality rates within 30 days from the initial infection in patients aged 65 and older with *S pneumoniae* pulmonary infections, even after adjusting for vaccination status.[163] Mortality in bacterial pneumonia may also be associated with the type of pathogen involved. While *S pneumoniae* is a common cause of

mortality, *Pseudomonas* species, *S aureus*, and polymicrobial infections exhibit higher mortality rates, possibly attributable to their virulence factors.[164][165][166][167]

If left untreated, pneumonia can result in an overall mortality rate of up to 30%.[162][168] A higher PSI score has been correlated with less favorable resolution of bacterial pneumonia by elevated inflammatory markers, anemia, confusion, and elevated blood urea nitrogen.[169] Early clinical failure is associated with persistent tachypnea, hypoxia, confusion, and arterial blood acidosis within the first 3 days of pneumonia treatment.[170] In VAP, a higher Acute Physiology and Chronic Health Evaluation II (APACHE II) score exceeding 21 or a Sequential Organ Failure Assessment (SOFA) score surpassing 6 increases the mortality risk, particularly if the elevated SOFA score persists a week after diagnosis.[171] When bacterial pneumonia coexists with comorbid viral respiratory infections such as influenza and COVID-19, there is an elevated mortality risk, underscoring the importance of vaccination in vulnerable and at-risk populations.[172][173]

Antimicrobial resistance is increasing globally, fueled by the extensive use of broad-spectrum antibiotics in human healthcare and the agricultural industry.[174][175] This trend restricts regional choices for antimicrobial treatment of bacterial pneumonia, escalates healthcare system expenses, and is linked to a poorer prognosis for patients with bacterial pneumonia [176].

Over the long term, nosocomial bacterial pneumonia has been linked to elevated mortality rates at 1 year, with a heightened risk among older patients residing in aged care institutions.[177] Among this demographic, factors such as compromised nutritional status, chronic steroid use, and preexisting comorbidities are associated with a poorer prognosis.[178] This underscores the significance of implementing regular and appropriate follow-up measures for at-risk population groups following bacterial pneumonia.

Complications

Bacterial pneumonia complications can be severe, leading to the exacerbation of preexisting comorbidities, respiratory failure, and sepsis associated with multiorgan failure and coagulopathy.[179][180][181] Other potential complications of bacterial pneumonia include:[48][161][182][183][184][185]

- Lung fibrosis
- Destruction of lung parenchyma
- Necrotizing pneumonia
- Impaired ventilatory function
- Cavitation
- Empyema
- Pulmonary abscess
- Meningitis
- Death

Deterrence and Patient Education

Patients should receive counseling to quit smoking, avoid alcohol intoxication, and maintain dental hygiene, as evidence suggests these behaviors may be risk factors for pneumonia.[146][186][187] Since bacterial pneumonia is transmitted by direct inoculation from fomites or respiratory droplets, emphasizing appropriate hand hygiene is crucial to prevent transmission.[188] Additionally, to prevent bacterial pneumonia, recommendations include:

- Vaccination against pneumococcus for older individuals and those who are immunocompromised [148]
- Annual vaccination against influenza for at-risk populations [189]
- Elderly and immunocompromised patients should be instructed to seek medical assistance as soon as they develop symptoms such as dyspnea, rigors, or fever [190]

Pearls and Other Issues

The pearls of bacterial pneumonia include:

- Most patients exhibit improvement within 48 to 72 hours [136][170]
- Chest X-ray findings lag behind clinical features and may take up to 8 weeks or longer to clear [191][192]
- If patients do not show improvement within 72 hours, an alternative cause should be suspected. Host factors need analysis, and considerations should include antibiotic resistance or the development of complications (eg, empyema) [170]

Enhancing Healthcare Team Outcomes

The management of pneumonia necessitates an interprofessional team to consider the patient's individual factors, comorbidities, and any resulting sequelae.[193] While most patients can be managed as outpatients, neglecting proper treatment for bacterial pneumonia may lead to elevated morbidity and mortality rates.[29][31]

In addition to pharmacotherapy, patients may require input from allied health professionals to address the underlying risk factors for bacterial pneumonia. This may involve speech pathology to manage dysphagia, psychological support for harm reduction in cases related to hazardous alcohol and intravenous drug use, consultation with a dietician for nutritional supplementation, and physiotherapy engagement for early mobilization.[153][159][194] A dental review and oral health management may reduce the incidence of pneumonia in residential aged-care facilities.[195] The treating clinician should continue to address underlying comorbidities, involve rehabilitation services when necessary, and provide regular encouragement for smoking cessation and alcohol abstinence.

Clinicians should actively promote adherence to appropriate influenza and pneumococcal vaccines.[148][189] Pharmacists play a crucial role in antimicrobial stewardship, ensuring responsible antimicrobial prescribing and educating patients about the importance of medication adherence while monitoring and addressing any adverse effects.[196][197] Antimicrobial stewardship pharmacists can guide antimicrobial choices, considering factors such as drug monitoring and drug-drug interactions, allergies, and renal and hepatic impairment.[198]

Nursing staff are critical for the daily nonpharmacological management of pneumonia in the inpatient setting, including cases of VAP. They may also participate in community vaccinations and provide education to at-risk patients.[199][200] Additionally, nurses can counsel patients on appropriate dosing and administration of medications, monitor treatment progress, and promptly report any issues to the managing clinician.

Finally, the treating clinician should encourage appropriate follow-up with patients to ensure the clinical resolution of their illness [150][151]. Successful management of pneumonia requires open communication and collaboration among the interprofessional team, working together to reduce the morbidity of pneumonia associated with this condition.

Review Questions

- [Access free multiple choice questions on this topic.](#)
- [Comment on this article.](#)

References

1. Yousaf Kazmi S. The etymology of microbial nomenclature and the diseases these cause in a historical perspective. *Saudi J Biol Sci.* 2022 Nov;29(11):103454. [PMC free article: [PMC9562425](#)] [PubMed: [36248774](#)]
2. Torres A, Cilloniz C, Niederman MS, Menéndez R, Chalmers JD, Wunderink RG, van der Poll T. Pneumonia. *Nat Rev Dis Primers.* 2021 Apr 08;7(1):25. [PubMed: [33833230](#)]
3. Grief SN, Loza JK. Guidelines for the Evaluation and Treatment of Pneumonia. *Prim Care.* 2018 Sep;45(3):485-503. [PMC free article: [PMC7112285](#)] [PubMed: [30115336](#)]
4. Ashurst JV, Dawson A. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 20, 2023. Klebsiella Pneumonia. [PubMed: [30085546](#)]
5. Mackenzie G. The definition and classification of pneumonia. *Pneumonia (Nathan).* 2016;8:14. [PMC free article: [PMC5471962](#)] [PubMed: [28702293](#)]
6. Miyashita N. Atypical pneumonia: Pathophysiology, diagnosis, and treatment. *Respir Investig.* 2022 Jan;60(1):56-67. [PubMed: [34750083](#)]
7. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. *Antimicrob Agents Chemother.* 2007 Oct;51(10):3568-73. [PMC free article: [PMC2043297](#)] [PubMed: [17682100](#)]
8. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016 Sep 01;63(5):e61-e111. [PMC free article: [PMC4981759](#)] [PubMed: [27418577](#)]
9. Akter S, Shamsuzzaman SM, Jahan F. Community acquired bacterial pneumonia: aetiology, laboratory detection and antibiotic susceptibility pattern. *Malays J Pathol.* 2014 Aug;36(2):97-103. [PubMed: [25194532](#)]
10. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. *Pneumonia (Nathan).* 2020;12:11. [PMC free article: [PMC7533148](#)] [PubMed: [33024653](#)]
11. Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M, Leuschner P, Ruiz-Buitrago S, Battaglia S, Fantini R, Pascual-Guardia S, Marin-Corral J, Restrepo MI, GLIMP Collaborators. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. *Eur J Clin Microbiol Infect Dis.* 2020 Aug;39(8):1513-1525. [PMC free article: [PMC7222990](#)] [PubMed: [32242314](#)]
12. Røysted W, Simonsen Ø, Jenkins A, Sarjomaa M, Svendsen MV, Ragnhildstveit E, Tveten Y, Kanestrøm A, Waage H, Ringstad J. Aetiology and risk factors of community-acquired pneumonia in hospitalized patients in Norway. *Clin Respir J.* 2016 Nov;10(6):756-764. [PubMed: [25764275](#)]
13. Peto L, Nadjm B, Horby P, Ngan TT, van Doorn R, Van Kinh N, Wertheim HF. The bacterial aetiology of adult community-acquired pneumonia in Asia: a systematic review. *Trans R Soc Trop Med Hyg.* 2014 Jun;108(6):326-37. [PMC free article: [PMC4023908](#)] [PubMed: [24781376](#)]
14. Niederman MS, Cilloniz C. Aspiration pneumonia. *Rev Esp Quimioter.* 2022 Apr;35 Suppl 1(Suppl 1):73-77. [PMC free article: [PMC9106188](#)] [PubMed: [35488832](#)]
15. Lynch JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. *Chest.* 2001 Feb;119(2 Suppl):373S-384S. [PubMed: [11171773](#)]
- 16.

- Htoutou Sedláková M, Pudová V, Kolář M. [Bacterial pathogens causing hospital-acquired pneumonia - a multicenter study in the Czech Republic]. *Klin Mikrobiol Infekc Lek*. 2015 Mar;21(1):10-4. [PubMed: 26098488]
17. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. *J Med Assoc Thai*. 2010 Jan;93 Suppl 1:S126-38. [PubMed: 20364567]
 18. Feng DY, Zhou YQ, Zou XL, Zhou M, Zhu JX, Wang YH, Zhang TT. Differences in microbial etiology between hospital-acquired pneumonia and ventilator-associated pneumonia: a single-center retrospective study in Guang Zhou. *Infect Drug Resist*. 2019;12:993-1000. [PMC free article: PMC6503191] [PubMed: 31118705]
 19. Manikam L, Lakhanpaul M. Epidemiology of community acquired pneumonia. *Paediatr Child Health (Oxford)*. 2012 Jul;22(7):299-306. [PMC free article: PMC7185481] [PubMed: 32362935]
 20. Bjarnason A, Westin J, Lindh M, Andersson LM, Kristinsson KG, Löve A, Baldursson O, Gottfredsson M. Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study. *Open Forum Infect Dis*. 2018 Feb;5(2):ofy010. [PMC free article: PMC5804852] [PubMed: 29479548]
 21. Partouche H, Lepoutre A, Vaure CBD, Poisson T, Toubiana L, Gilberg S. Incidence of all-cause adult community-acquired pneumonia in primary care settings in France. *Med Mal Infect*. 2018 Sep;48(6):389-395. [PubMed: 29656842]
 22. Zhu YG, Tang XD, Lu YT, Zhang J, Qu JM. Contemporary Situation of Community-acquired Pneumonia in China: A Systematic Review. *J Transl Int Med*. 2018 Mar;6(1):26-31. [PMC free article: PMC5874484] [PubMed: 29607301]
 23. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease mortality in the United States during the 20th century. *JAMA*. 1999 Jan 06;281(1):61-6. [PubMed: 9892452]
 24. Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, Persaud AK, Raghuram A, Fernandez F, Beavin L, Bosson R, Fernandez-Botran R, Cavallazzi R, Bordon J, Valdivieso C, Schulte J, Carrico RM., University of Louisville Pneumonia Study Group. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. *Clin Infect Dis*. 2017 Nov 13;65(11):1806-1812. [PubMed: 29020164]
 25. Brown JD, Harnett J, Chambers R, Sato R. The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States. *BMC Geriatr*. 2018 Apr 16;18(1):92. [PMC free article: PMC5902892] [PubMed: 29661135]
 26. Mizgerd JP. Lung infection--a public health priority. *PLoS Med*. 2006 Feb;3(2):e76. [PMC free article: PMC1326257] [PubMed: 16401173]
 27. Shin EJ, Kim Y, Jeong JY, Jung YM, Lee MH, Chung EH. The changes of prevalence and etiology of pediatric pneumonia from National Emergency Department Information System in Korea, between 2007 and 2014. *Korean J Pediatr*. 2018 Sep;61(9):291-300. [PMC free article: PMC6172518] [PubMed: 30274507]
 28. Lutfiyya MN, Henley E, Chang LF, Reyburn SW. Diagnosis and treatment of community-acquired pneumonia. *Am Fam Physician*. 2006 Feb 01;73(3):442-50. [PubMed: 16477891]
 29. Labarere J, Stone RA, Obrosky DS, Yealy DM, Meehan TP, Fine JM, Graff LG, Fine MJ. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: A propensity-adjusted analysis. *Chest*. 2007 Feb;131(2):480-8. [PubMed: 17296651]
 30. Theilacker C, Sprenger R, Leverkus F, Walker J, Häckl D, von Eiff C, Schiffner-Rohe J. Population-based incidence and mortality of community-acquired pneumonia in Germany. *PLoS One*. 2021;16(6):e0253118. [PMC free article: PMC8205119] [PubMed: 34129632]
 31. Arnold FW, Wiemken TL, Peyrani P, Ramirez JA, Brock GN., CAPO authors. Mortality differences among hospitalized patients with community-acquired pneumonia in three

- world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. *Respir Med*. 2013 Jul;107(7):1101-11. [PubMed: 23660396]
32. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. *Am J Respir Crit Care Med*. 2002 Sep 01;166(5):717-23. [PubMed: 12204871]
33. Minogue MF, Coley CM, Fine MJ, Marrie TJ, Kapoor WN, Singer DE. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. *Ann Emerg Med*. 1998 Mar;31(3):376-80. [PubMed: 9506497]
34. Montón C, Torres A. Lung inflammatory response in pneumonia. *Monaldi Arch Chest Dis*. 1998 Feb;53(1):56-63. [PubMed: 9632909]
35. Korkmaz FT, Traber KE. Innate immune responses in pneumonia. *Pneumonia (Nathan)*. 2023 Feb 25;15(1):4. [PMC free article: PMC9957695] [PubMed: 36829255]
36. Branger J, Knapp S, Weijer S, Leemans JC, Pater JM, Speelman P, Florquin S, van der Poll T. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. *Infect Immun*. 2004 Feb;72(2):788-94. [PMC free article: PMC321591] [PubMed: 14742522]
37. Phillips-Houlbracq M, Ricard JD, Foucrier A, Yoder-Himes D, Gaudry S, Bex J, Messika J, Margetis D, Chatel J, Dobrindt U, Denamur E, Roux D. Pathophysiology of *Escherichia coli* pneumonia: Respective contribution of pathogenicity islands to virulence. *Int J Med Microbiol*. 2018 Mar;308(2):290-296. [PubMed: 29325882]
38. Nelson AL, Roche AM, Gould JM, Chim K, Ratner AJ, Weiser JN. Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. *Infect Immun*. 2007 Jan;75(1):83-90. [PMC free article: PMC1828419] [PubMed: 17088346]
39. Chaudhry R, Varshney AK, Malhotra P. Adhesion proteins of *Mycoplasma pneumoniae*. *Front Biosci*. 2007 Jan 01;12:690-9. [PubMed: 17127329]
40. Lucas CE, Brown E, Fields BS. Type IV pili and type II secretion play a limited role in *Legionella pneumophila* biofilm colonization and retention. *Microbiology (Reading)*. 2006 Dec;152(Pt 12):3569-3573. [PubMed: 17159209]
41. Xiang J, Rir-Sim-Ah J, Tesfaigzi Y. IL-9 and IL-13 induce mucous cell metaplasia that is reduced by IFN-gamma in a Bax-mediated pathway. *Am J Respir Cell Mol Biol*. 2008 Mar;38(3):310-7. [PMC free article: PMC2258450] [PubMed: 17901408]
42. Dellamonica J, Lerolle N, Sargentini C, Beduneau G, Di Marco F, Mercat A, Richard JC, Diehl JL, Mancebo J, Rouby JJ, Lu Q, Bernardin G, Brochard L. PEEP-induced changes in lung volume in acute respiratory distress syndrome. Two methods to estimate alveolar recruitment. *Intensive Care Med*. 2011 Oct;37(10):1595-604. [PubMed: 21866369]
43. Kass SM, Williams PM, Reamy BV. Pleurisy. *Am Fam Physician*. 2007 May 01;75(9):1357-64. [PubMed: 17508531]
44. Reimel BA, Krishnadasen B, Cuschieri J, Klein MB, Gross J, Karmy-Jones R. Surgical management of acute necrotizing lung infections. *Can Respir J*. 2006 Oct;13(7):369-73. [PMC free article: PMC2683290] [PubMed: 17036090]
45. Zinserling VA, Swistunov VV, Botvinkin AD, Stepanenko LA, Makarova AE. Lobar (croupous) pneumonia: old and new data. *Infection*. 2022 Feb;50(1):235-242. [PMC free article: PMC8409273] [PubMed: 34472009]
46. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. *Thorax*. 2013 Nov;68(11):1057-65. [PMC free article: PMC3812874] [PubMed: 24130229]
47. Almirall J, Serra-Prat M, Bolibar I, Balasso V. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies. *Respiration*. 2017;94(3):299-311. [PubMed: 28738364]
48. Johnston ID, Strachan DP, Anderson HR. Effect of pneumonia and whooping cough in childhood on adult lung function. *N Engl J Med*. 1998 Feb 26;338(9):581-7. [PubMed: 9475765]

49. Hind CR. Pulmonary complications of intravenous drug misuse. 2. Infective and HIV related complications. *Thorax*. 1990 Dec;45(12):957-61. [PMC free article: [PMC462846](#)] [PubMed: [2281430](#)]
50. Straus WL, Plouffe JF, File TM, Lipman HB, Hackman BH, Salstrom SJ, Benson RF, Breiman RF. Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group. *Arch Intern Med*. 1996 Aug 12-26;156(15):1685-92. [PubMed: [8694667](#)]
51. Jernigan DB, Hofmann J, Cetron MS, Genese CA, Nuorti JP, Fields BS, Benson RF, Carter RJ, Edelstein PH, Guerrero IC, Paul SM, Lipman HB, Breiman R. Outbreak of Legionnaires' disease among cruise ship passengers exposed to a contaminated whirlpool spa. *Lancet*. 1996 Feb 24;347(9000):494-9. [PubMed: [8596266](#)]
52. Mouchtouri VA, Rudge JW. Legionnaires' Disease in Hotels and Passenger Ships: A Systematic Review of Evidence, Sources, and Contributing Factors. *J Travel Med*. 2015 Sep-Oct;22(5):325-37. [PubMed: [26220258](#)]
53. Howie SR, Schellenberg J, Chimah O, Ideh RC, Ebruke BE, Oluwalana C, Mackenzie G, Jallow M, Njie M, Donkor S, Dionisio KL, Goldberg G, Fornace K, Bottomley C, Hill PC, Grant CC, Corrah T, Prentice AM, Ezzati M, Greenwood BM, Smith PG, Adegbola RA, Mulholland K. Childhood pneumonia and crowding, bed-sharing and nutrition: a case-control study from The Gambia. *Int J Tuberc Lung Dis*. 2016 Oct;20(10):1405-1415. [PMC free article: [PMC5019143](#)] [PubMed: [27725055](#)]
54. Pelissari DM, Diaz-Quijano FA. Household crowding as a potential mediator of socioeconomic determinants of tuberculosis incidence in Brazil. *PLoS One*. 2017;12(4):e0176116. [PMC free article: [PMC5395230](#)] [PubMed: [28419146](#)]
55. Taylor-Robinson D. The importance of mycoplasmas in respiratory infections. *Dev Biol Stand*. 1975;28:86-100. [PubMed: [1092579](#)]
56. Blasi F, Tarsia P, Arosio C, Fagetti L, Allegra L. Epidemiology of Chlamydia pneumoniae. *Clin Microbiol Infect*. 1998 Jan;4 Suppl 4:S1-S6. [PubMed: [11869264](#)]
57. Berk Y, Klaassen CH, Mouton JW, Meis JF. [An outbreak of psittacosis at a bird-fanciers fair in the Netherlands]. *Ned Tijdschr Geneesk*. 2008 Aug 23;152(34):1889-92. [PubMed: [18788682](#)]
58. Tärnvik A, Berglund L. Tularaemia. *Eur Respir J*. 2003 Feb;21(2):361-73. [PubMed: [12608453](#)]
59. Eden JS, Rose K, Ng J, Shi M, Wang Q, Sintchenko V, Holmes EC. Francisella tularensis ssp. holarctica in Ringtail Possums, Australia. *Emerg Infect Dis*. 2017 Jul;23(7):1198-1201. [PMC free article: [PMC5512506](#)] [PubMed: [28628459](#)]
60. Cleri DJ, Vernaleo JR, Lombardi LJ, Rabbat MS, Mathew A, Marton R, Reyelt MC. Plague pneumonia disease caused by Yersinia pestis. *Semin Respir Infect*. 1997 Mar;12(1):12-23. [PubMed: [9097371](#)]
61. Hill MK, Sanders CV. Leptospiral pneumonia. *Semin Respir Infect*. 1997 Mar;12(1):44-9. [PubMed: [9097376](#)]
62. Smit LA, van der Sman-de Beer F, Opstal-van Winden AW, Hooiveld M, Beekhuizen J, Wouters IM, Yzermans J, Heederik D. Q fever and pneumonia in an area with a high livestock density: a large population-based study. *PLoS One*. 2012;7(6):e38843. [PMC free article: [PMC3369851](#)] [PubMed: [22685612](#)]
63. Flint J, Dalton CB, Merritt TD, Graves S, Ferguson JK, Osbourn M, Eastwood K, Durrheim DN. Q fever and contact with kangaroos in New South Wales. *Commun Dis Intell Q Rep*. 2016 Jun 30;40(2):E202-3. [PubMed: [27522129](#)]
64. Goodrick I, Todd G, Stewart J. Soil characteristics influencing the spatial distribution of melioidosis in Far North Queensland, Australia. *Epidemiol Infect*. 2018 Sep;146(12):1602-1607. [PMC free article: [PMC9507928](#)] [PubMed: [29970213](#)]
65. Gransden WR, Leibovici L, Eykyn SJ, Pitlik SD, Samra Z, Konisberger H, Drucker M, Phillips I. Risk factors and a clinical index for diagnosis of Pseudomonas aeruginosa bacteremia. *Clin Microbiol Infect*. 1995 Feb;1(2):119-123. [PubMed: [11866739](#)]

66. BELCHER JR. The pulmonary complications of dysphagia. *Thorax*. 1949 Mar;4(1):44-56. [PMC free article: [PMC1018288](#)] [PubMed: [18113256](#)]
67. Manabe T, Teramoto S, Tamiya N, Okochi J, Hizawa N. Risk Factors for Aspiration Pneumonia in Older Adults. *PLoS One*. 2015;10(10):e0140060. [PMC free article: [PMC4596873](#)] [PubMed: [26444916](#)]
68. Langmore SE, Terpenning MS, Schork A, Chen Y, Murray JT, Lopatin D, Loesche WJ. Predictors of aspiration pneumonia: how important is dysphagia? *Dysphagia*. 1998 Spring;13(2):69-81. [PubMed: [9513300](#)]
69. Chin CL, Manzel LJ, Lehman EE, Humlicek AL, Shi L, Starner TD, Denning GM, Murphy TF, Sethi S, Look DC. Haemophilus influenzae from patients with chronic obstructive pulmonary disease exacerbation induce more inflammation than colonizers. *Am J Respir Crit Care Med*. 2005 Jul 01;172(1):85-91. [PMC free article: [PMC2718449](#)] [PubMed: [15805181](#)]
70. Herrod HG, Gross S, Insel R. Selective antibody deficiency to Haemophilus influenzae type B capsular polysaccharide vaccination in children with recurrent respiratory tract infection. *J Clin Immunol*. 1989 Sep;9(5):429-34. [PubMed: [2621246](#)]
71. Justiz Vaillant AA, Naik R. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 27, 2023. HIV-1–Associated Opportunistic Infections. [PubMed: [30969609](#)]
72. Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. *JAMA*. 1997 Nov 05;278(17):1440-5. [PubMed: [9356004](#)]
73. Pneumonia. *Halls J Health*. 1880 Jan;27(1):1-3. [PMC free article: [PMC9215394](#)] [PubMed: [36489311](#)]
74. Miravittles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. *Eur Respir J*. 2012 Jun;39(6):1354-60. [PubMed: [22034649](#)]
75. WELFORD NT. Recovery from primary Friedlander pneumonia (type B) on therapy with sulfadiazine and penicillin. *Ill Med J*. 1946 Sep;90:185-7. [PubMed: [20998872](#)]
76. Bartlett JG, Finegold SM. Anaerobic infections of the lung and pleural space. *Am Rev Respir Dis*. 1974 Jul;110(1):56-77. [PubMed: [4834618](#)]
77. Johnson JD, Raff MJ, Van Arsdall JA. Neurologic manifestations of Legionnaires' disease. *Medicine (Baltimore)*. 1984 Sep;63(5):303-10. [PubMed: [6088942](#)]
78. Chitasombat MN, Ratchatanawin N, Visessiri Y. Disseminated extrapulmonary Legionella pneumophila infection presenting with panniculitis: case report and literature review. *BMC Infect Dis*. 2018 Sep 17;18(1):467. [PMC free article: [PMC6142325](#)] [PubMed: [30223775](#)]
79. Wipf JE, Lipsky BA, Hirschmann JV, Boyko EJ, Takasugi J, Peugeot RL, Davis CL. Diagnosing pneumonia by physical examination: relevant or relic? *Arch Intern Med*. 1999 May 24;159(10):1082-7. [PubMed: [10335685](#)]
80. Htun TP, Sun Y, Chua HL, Pang J. Clinical features for diagnosis of pneumonia among adults in primary care setting: A systematic and meta-review. *Sci Rep*. 2019 May 20;9(1):7600. [PMC free article: [PMC6527561](#)] [PubMed: [31110214](#)]
81. Saldías F, Méndez JI, Ramírez D, Díaz O. [Predictive value of history and physical examination for the diagnosis of community-acquired pneumonia in adults: a literature review]. *Rev Med Chil*. 2007 Apr;135(4):517-28. [PubMed: [17554463](#)]
82. Claudius I, Baraff LJ. Pediatric emergencies associated with fever. *Emerg Med Clin North Am*. 2010 Feb;28(1):67-84, vii-viii. [PubMed: [19945599](#)]
83. Singhi S, Dhawan A, Kataria S, Walia BN. Clinical signs of pneumonia in infants under 2 months. *Arch Dis Child*. 1994 May;70(5):413-7. [PMC free article: [PMC1029831](#)] [PubMed: [8017964](#)]
84. Kevat PM, Morpeth M, Graham H, Gray AZ. A systematic review of the clinical features of pneumonia in children aged 5-9 years: Implications for guidelines and research. *J Glob Health*. 2022;12:10002. [PMC free article: [PMC8943783](#)] [PubMed: [35356655](#)]
- 85.

- Ayalon I, Glatstein MM, Zaidenberg-Israeli G, Scolnik D, Ben Tov A, Ben Sira L, Reif S. The role of physical examination in establishing the diagnosis of pneumonia. *Pediatr Emerg Care*. 2013 Aug;29(8):893-6. [PubMed: 23903669]
86. Musgrave T, Verghese A. Clinical features of pneumonia in the elderly. *Semin Respir Infect*. 1990 Dec;5(4):269-75. [PubMed: 2093972]
 87. Niederman MS, Fein AM. Sepsis syndrome, the adult respiratory distress syndrome, and nosocomial pneumonia. A common clinical sequence. *Clin Chest Med*. 1990 Dec;11(4):633-56. [PubMed: 2268994]
 88. Cunha BA, Quintiliani R. The atypical pneumonias: a diagnostic and therapeutic approach. *Postgrad Med*. 1979 Sep;66(3):95-102. [PubMed: 471855]
 89. Newman MG. Anaerobic oral and dental infection. *Rev Infect Dis*. 1984 Mar-Apr;6 Suppl 1:S107-14. [PubMed: 6372018]
 90. Dodiuk-Gad R, Cohen E, Ziv M, Goldstein LH, Chazan B, Shafer J, Sprecher H, Elias M, Keness Y, Rozenman D. Cutaneous nocardiosis: report of two cases and review of the literature. *Int J Dermatol*. 2010 Dec;49(12):1380-5. [PubMed: 21155087]
 91. Roberts DB. The etiology of bullous myringitis and the role of mycoplasmas in ear disease: a review. *Pediatrics*. 1980 Apr;65(4):761-6. [PubMed: 7367083]
 92. Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. *J Prev Med Hyg*. 2017 Mar;58(1):E9-E12. [PMC free article: PMC5432783] [PubMed: 28515626]
 93. Varo R, Bila R, Saavedra B, Siteo A, Uamusse A, Ribó-Aristizabal JL, García-Basteiro AL. Paraplegia and spinal deformity in a Mozambican child with Pott's disease and tuberculous scrofula. *Lancet*. 2019 Nov 02;394(10209):1651. [PubMed: 31690448]
 94. Sezer B, Akdeniz BG, Günbay S, Hilmioğlu-Polat S, Başdemir G. Actinomycosis osteomyelitis of the jaws: Report of four cases and a review of the literature. *J Dent Sci*. 2017 Sep;12(3):301-307. [PMC free article: PMC6400081] [PubMed: 30895066]
 95. Mabeza GF, Macfarlane J. Pulmonary actinomycosis. *Eur Respir J*. 2003 Mar;21(3):545-51. [PubMed: 12662015]
 96. Reyes LF, Bastidas AR, Quintero ET, Frías JS, Aguilar ÁF, Pedreros KD, Herrera M, Saza LD, Nonzoque AP, Bello LE, Hernández MD, Carmona GA, Jaimes A, Ramírez SM, Murillo N. Performance of the CORB (Confusion, Oxygenation, Respiratory Rate, and Blood Pressure) Scale for the Prediction of Clinical Outcomes in Pneumonia. *Can Respir J*. 2022;2022:4493777. [PMC free article: PMC9187474] [PubMed: 35692950]
 97. Memon RA, Rashid MA, Avva S, Anirudh Chunchu V, Ijaz H, Ahmad Ganaie Z, Kabir Dar A, Ali N. The Use of the SMART-COP Score in Predicting Severity Outcomes Among Patients With Community-Acquired Pneumonia: A Meta-Analysis. *Cureus*. 2022 Jul;14(7):e27248. [PMC free article: PMC9409612] [PubMed: 36043007]
 98. Karmakar G, Wilsher M. Use of the 'CURB 65' score in hospital practice. *Intern Med J*. 2010 Dec;40(12):828-32. [PubMed: 19811559]
 99. Quinton LJ, Walkey AJ, Mizgerd JP. Integrative Physiology of Pneumonia. *Physiol Rev*. 2018 Jul 01;98(3):1417-1464. [PMC free article: PMC6088146] [PubMed: 29767563]
 100. Johansson N, Kalin M, Giske CG, Hedlund J. Quantitative detection of *Streptococcus pneumoniae* from sputum samples with real-time quantitative polymerase chain reaction for etiologic diagnosis of community-acquired pneumonia. *Diagn Microbiol Infect Dis*. 2008 Mar;60(3):255-61. [PubMed: 18036762]
 101. Strålin K, Törnqvist E, Kaltoft MS, Olcén P, Holmberg H. Etiologic diagnosis of adult bacterial pneumonia by culture and PCR applied to respiratory tract samples. *J Clin Microbiol*. 2006 Feb;44(2):643-5. [PMC free article: PMC1392682] [PubMed: 16455935]
 102. Kang YA, Kwon SY, Yoon HI, Lee JH, Lee CT. Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia. *Korean J Intern Med*. 2009 Dec;24(4):337-42. [PMC free article: PMC2784977] [PubMed: 19949732]
 - 103.

- Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. *Respir Med*. 2001 Jan;95(1):78-82. [PubMed: 11207022]
104. Kennedy M, Bates DW, Wright SB, Ruiz R, Wolfe RE, Shapiro NI. Do emergency department blood cultures change practice in patients with pneumonia? *Ann Emerg Med*. 2005 Nov;46(5):393-400. [PubMed: 16271664]
 105. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. *Mayo Clin Proc*. 1975 Jun;50(6):339-44. [PubMed: 1127999]
 106. Rosón B, Carratalà J, Verdager R, Dorca J, Manresa F, Gudiol F. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. *Clin Infect Dis*. 2000 Oct;31(4):869-74. [PubMed: 11049763]
 107. Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. *J Clin Microbiol*. 2003 Oct;41(10):4497-501. [PMC free article: PMC254378] [PubMed: 14532173]
 108. Muricy EC, Lemes RA, Bombarda S, Ferrazoli L, Chimara E. Differentiation between *Nocardia* spp. and *Mycobacterium* spp.: Critical aspects for bacteriological diagnosis. *Rev Inst Med Trop Sao Paulo*. 2014 Sep-Oct;56(5):397-401. [PMC free article: PMC4172110] [PubMed: 25229219]
 109. Burckhardt I, Panitz J, Burckhardt F, Zimmermann S. Identification of *Streptococcus pneumoniae*: Development of a Standardized Protocol for Optochin Susceptibility Testing Using Total Lab Automation. *Biomed Res Int*. 2017;2017:4174168. [PMC free article: PMC5376432] [PubMed: 28401155]
 110. Porter BD, Ortika BD, Satzke C. Capsular Serotyping of *Streptococcus pneumoniae* by latex agglutination. *J Vis Exp*. 2014 Sep 25;(91):51747. [PMC free article: PMC4828145] [PubMed: 25285991]
 111. Arjun R, Padmanabhan A, Reddy Attunuru BP, Gupta P. Disseminated nocardiosis masquerading as metastatic malignancy. *Lung India*. 2016 Jul-Aug;33(4):434-8. [PMC free article: PMC4948235] [PubMed: 27578940]
 112. Kelava I, Marecic V, Fucak P, Ivek E, Kolaric D, Ozanic M, Mihelcic M, Santic M. Optimisation of External Factors for the Growth of *Francisella novicida* within *Dictyostelium discoideum*. *Biomed Res Int*. 2020;2020:6826983. [PMC free article: PMC6996686] [PubMed: 32090107]
 113. Bayot ML, Bragg BN. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 10, 2022. Antimicrobial Susceptibility Testing. [PubMed: 30969536]
 114. Schuetz P, Haubitz S, Christ-Crain M, Albrich WC, Zimmerli W, Mueller B., ProHOSP Study Group. Hyponatremia and anti-diuretic hormone in Legionnaires' disease. *BMC Infect Dis*. 2013 Dec 11;13:585. [PMC free article: PMC3880094] [PubMed: 24330484]
 115. Helms CM, Viner JP, Sturm RH, Renner ED, Johnson W. Comparative features of pneumococcal, mycoplasmal, and Legionnaires' disease pneumonias. *Ann Intern Med*. 1979 Apr;90(4):543-7. [PubMed: 434631]
 116. Franquet T. Imaging of Community-acquired Pneumonia. *J Thorac Imaging*. 2018 Sep;33(5):282-294. [PubMed: 30036297]
 117. Macfarlane J, Rose D. Radiographic features of staphylococcal pneumonia in adults and children. *Thorax*. 1996 May;51(5):539-40. [PMC free article: PMC473606] [PubMed: 8711686]
 118. Joseph JP, Meddows TR, Webster DP, Newton JD, Myerson SG, Prendergast B, Scarborough M, Herring N. Prioritizing echocardiography in *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother*. 2013 Feb;68(2):444-9. [PubMed: 23111851]
 119. King P. *Haemophilus influenzae* and the lung (*Haemophilus* and the lung). *Clin Transl Med*. 2012 Jun 14;1(1):10. [PMC free article: PMC3567431] [PubMed: 23369277]
 120. Grover SB, Grover H, Antil N, Patra S, Sen MK, Nair D. Imaging Approach to Pulmonary Infections in the Immunocompromised Patient. *Indian J Radiol Imaging*. 2022 Mar;32(1):81-112. [PMC free article: PMC9205686] [PubMed: 35722641]
 - 121.

- Schmidt AJ, Stark P. Radiographic findings in Klebsiella (Friedlander's) pneumonia: the bulging fissure sign. *Semin Respir Infect.* 1998 Mar;13(1):80-2. [PubMed: 9543478]
122. Francis JB, Francis PB. Bulging (sagging) fissure sign in Hemophilus influenzae lobar pneumonia. *South Med J.* 1978 Nov;71(11):1452-3. [PubMed: 309660]
 123. Raju S, Ghosh S, Mehta AC. Chest CT Signs in Pulmonary Disease: A Pictorial Review. *Chest.* 2017 Jun;151(6):1356-1374. [PubMed: 28212835]
 124. Sanchez Nieto JM, Carillo Alcaraz A. The role of bronchoalveolar lavage in the diagnosis of bacterial pneumonia. *Eur J Clin Microbiol Infect Dis.* 1995 Oct;14(10):839-50. [PMC free article: PMC7102128] [PubMed: 8605896]
 125. Hanretty AM, Gallagher JC. Shortened Courses of Antibiotics for Bacterial Infections: A Systematic Review of Randomized Controlled Trials. *Pharmacotherapy.* 2018 Jun;38(6):674-687. [PubMed: 29679383]
 126. Ayede AI, Kirolos A, Fowobaje KR, Williams LJ, Bakare AA, Oyewole OB, Olorunfemi OB, Kuna O, Iwuala NT, Oguntoye A, Kusoro SO, Okunlola ME, Qazi SA, Nair H, Falade AG, Campbell H. A prospective validation study in South-West Nigeria on caregiver report of childhood pneumonia and antibiotic treatment using Demographic and Health Survey (DHS) and Multiple Indicator Cluster Survey (MICS) questions. *J Glob Health.* 2018 Dec;8(2):020806. [PMC free article: PMC6150611] [PubMed: 30254744]
 127. Julián-Jiménez A, Adán Valero I, Beteta López A, Cano Martín LM, Fernández Rodríguez O, Rubio Díaz R, Sepúlveda Berrocal MA, González Del Castillo J, Candel González FJ., CAP group (community-acquired pneumonia) from the Infections in Emergencies - Sepsis Code working group. [Recommendations for the care of patients with community-acquired pneumonia in the Emergency Department]. *Rev Esp Quimioter.* 2018 Apr;31(2):186-202. [PMC free article: PMC6159381] [PubMed: 29619807]
 128. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. *Eur J Clin Microbiol Infect Dis.* 2014 Jul;33(7):1065-79. [PMC free article: PMC4042014] [PubMed: 24532008]
 129. Nayar S, Hasan A, Waghay P, Ramanathan S, Ahdal J, Jain R. Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies. *Lung India.* 2019 Nov-Dec;36(6):525-533. [PMC free article: PMC6852216] [PubMed: 31670301]
 130. Trad MA, Baisch A. Management of community-acquired pneumonia in an Australian regional hospital. *Aust J Rural Health.* 2017 Apr;25(2):120-124. [PubMed: 26689428]
 131. Ba B, Gaudin K, Désiré A, Phoeung T, Langlois MH, Behl CR, Unowsky J, Patel IH, Malick AW, Gomes M, White N, Kauss T. Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions. *Antimicrob Agents Chemother.* 2018 Dec;62(12) [PMC free article: PMC6256799] [PubMed: 30348664]
 132. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med.* 2019 Oct 01;200(7):e45-e67. [PMC free article: PMC6812437] [PubMed: 31573350]
 133. Sader HS, Huband MD, Castanheira M, Flamm RK. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States. *Antimicrob Agents Chemother.* 2017 Mar;61(3) [PMC free article: PMC5328569] [PubMed: 28069652]
 134. Plaisance KI, Mackowiak PA. Antipyretic therapy: physiologic rationale, diagnostic implications, and clinical consequences. *Arch Intern Med.* 2000 Feb 28;160(4):449-56. [PubMed: 10695685]
 - 135.

- Rodríguez A, Mendia A, Sirvent JM, Barcenilla F, de la Torre-Prados MV, Solé-Violán J, Rello J., CAPUCI Study Group. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. *Crit Care Med*. 2007 Jun;35(6):1493-8. [PubMed: 17452932]
136. Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M, Lobo JL, Tomás L, Camino J, Nuñez J, Capelastegui A. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial. *JAMA Intern Med*. 2016 Sep 01;176(9):1257-65. [PubMed: 27455166]
 137. Lee JH, Park YH, Kang DR, Lee SJ, Lee MK, Kim SH, Yong SJ, Lee WY. Risk of Pneumonia Associated with Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease: A Korean Population-Based Study. *Int J Chron Obstruct Pulmon Dis*. 2020;15:3397-3406. [PMC free article: PMC7778438] [PubMed: 33402820]
 138. De Pascale G, Bello G, Antonelli M. Steroids in severe pneumonia: a literature review. *Minerva Anesthesiol*. 2011 Sep;77(9):902-10. [PubMed: 21878872]
 139. Harris P, Bennett A. Waterhouse-Friderichsen syndrome. *N Engl J Med*. 2001 Sep 13;345(11):841. [PubMed: 11556316]
 140. Hamilton D, Harris MD, Foweraker J, Gresham GA. Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection. *J Clin Pathol*. 2004 Feb;57(2):208-9. [PMC free article: PMC1770213] [PubMed: 14747454]
 141. Saleem N, Kulkarni A, Snow TAC, Ambler G, Singer M, Arulkumaran N. Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. *Chest*. 2023 Mar;163(3):484-497. [PMC free article: PMC10808071] [PubMed: 36087797]
 142. Dequin PF, Meziani F, Quenot JP, Kamel T, Ricard JD, Badie J, Reignier J, Heming N, Plantefève G, Souweine B, Voiriot G, Colin G, Frat JP, Mira JP, Barbarot N, François B, Louis G, Gibot S, Guitton C, Giacardi C, Hraiech S, Vimeux S, L'Her E, Faure H, Herbrecht JE, Bouisse C, Joret A, Terzi N, Gacouin A, Quentin C, Jourdain M, Leclerc M, Coffre C, Bourgoin H, Lengellé C, Caille-Fénérol C, Giraudeau B, Le Gouge A., CRICS-TriGGERSep Network. Hydrocortisone in Severe Community-Acquired Pneumonia. *N Engl J Med*. 2023 May 25;388(21):1931-1941. [PubMed: 36942789]
 143. Ferrer M, Cosentini R, Nava S. The use of non-invasive ventilation during acute respiratory failure due to pneumonia. *Eur J Intern Med*. 2012 Jul;23(5):420-8. [PMC free article: PMC7126754] [PubMed: 22726370]
 144. Dransfield MT, Crim C, Criner GJ, Day NC, Halpin DMG, Han MK, Jones CE, Kilbride S, LaFon D, Lipson DA, Lomas DA, Martin N, Martinez FJ, Singh D, Wise RA, Lange P. Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT. *Ann Am Thorac Soc*. 2021 May;18(5):788-798. [PMC free article: PMC8086537] [PubMed: 33108212]
 145. Heo JY, Song JY, Noh JY, Choi MJ, Yoon JG, Lee SN, Cheong HJ, Kim WJ. Effects of influenza immunization on pneumonia in the elderly. *Hum Vaccin Immunother*. 2018 Mar 04;14(3):744-749. [PMC free article: PMC5861791] [PubMed: 29135343]
 146. Baskaran V, Murray RL, Hunter A, Lim WS, McKeever TM. Effect of tobacco smoking on the risk of developing community acquired pneumonia: A systematic review and meta-analysis. *PLoS One*. 2019;14(7):e0220204. [PMC free article: PMC6638981] [PubMed: 31318967]
 147. Connor E, Rasiah K, Hillock N. Utilisation of antimicrobials used to treat bacterial pneumonia in principal referral hospitals during the COVID-19 pandemic, Australia, 2020. *Commun Dis Intell* (2018). 2022 Feb 16;46 [PubMed: 35168505]
 148. Hsiao A, Hansen J, Timbol J, Lewis N, Isturiz R, Alexander-Parrish R, McLaughlin JM, Gessner BD, Klein NP. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated

- and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine. *JAMA Netw Open*. 2022 Mar 01;5(3):e221111. [PMC free article: [PMC8933738](#)] [PubMed: [35302634](#)]
149. Jones B, Waterer G. Advances in community-acquired pneumonia. *Ther Adv Infect Dis*. 2020 Jan-Dec;7:2049936120969607. [PMC free article: [PMC7656869](#)] [PubMed: [33224494](#)]
 150. Rose MA, Barker M, Liese J, Adams O, Ankermann T, Baumann U, Brinkmann F, Bruns R, Dahlheim M, Ewig S, Forster J, Hofmann G, Kemen C, Lück C, Nadal D, Nüblein T, Regamey N, Riedler J, Schmidt S, Schwerk N, Seidenberg J, Tenenbaum T, Trapp S, van der Linden M. [Guidelines for the Management of Community Acquired Pneumonia in Children and Adolescents (Pediatric Community Acquired Pneumonia, pCAP) - Issued under the Responsibility of the German Society for Pediatric Infectious Diseases (DGPI) and the German Society for Pediatric Pulmonology (GPP)]. *Pneumologie*. 2020 Aug;74(8):515-544. [PubMed: [32823360](#)]
 151. Baskaran V, Pearce F, Harwood RH, McKeever TM, Lim WS. Primary care consultations after hospitalisation for pneumonia: a large population-based cohort study. *Br J Gen Pract*. 2021 Apr;71(705):e250-e257. [PMC free article: [PMC8007276](#)] [PubMed: [33753348](#)]
 152. Hooper L, Abdelhamid A, Ajabnoor SM, Esio-Bassey C, Brainard J, Brown TJ, Bunn D, Foster E, Hammer CC, Hanson S, Jimoh FO, Maimouni H, Sandhu M, Wang X, Winstanley L, Cross JL, Welch AA, Rees K, Philpott C. Effects of fluid and drinking on pneumonia mortality in older adults: A systematic review and meta-analysis. *Clin Nutr ESPEN*. 2022 Feb;47:96-105. [PMC free article: [PMC8631606](#)] [PubMed: [35063249](#)]
 153. Bott J, Blumenthal S, Buxton M, Ellum S, Falconer C, Garrod R, Harvey A, Hughes T, Lincoln M, Mikelsons C, Potter C, Pryor J, Rimington L, Sinfield F, Thompson C, Vaughn P, White J., British Thoracic Society Physiotherapy Guideline Development Group. Guidelines for the physiotherapy management of the adult, medical, spontaneously breathing patient. *Thorax*. 2009 May;64 Suppl 1:i1-51. [PubMed: [19406863](#)]
 154. Meli A, Barbeta Viñas E, Battaglini D, Li Bassi G, Yang H, Yang M, Bobi J, Motos A, Fernández-Barat L, Chiumello D, Pelosi P, Torres A. Lateral position during severe mono-lateral pneumonia: an experimental study. *Sci Rep*. 2020 Nov 09;10(1):19372. [PMC free article: [PMC7653044](#)] [PubMed: [33168922](#)]
 155. Sud S, Friedrich JO, Taccone P, Polli F, Adhikari NK, Latini R, Pesenti A, Guérin C, Mancebo J, Curley MA, Fernandez R, Chan MC, Beuret P, Voggenreiter G, Sud M, Tognoni G, Gattinoni L. Prone ventilation reduces mortality in patients with acute respiratory failure and severe hypoxemia: systematic review and meta-analysis. *Intensive Care Med*. 2010 Apr;36(4):585-99. [PubMed: [20130832](#)]
 156. Drakulovic MB, Torres A, Bauer TT, Nicolas JM, Nogué S, Ferrer M. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. *Lancet*. 1999 Nov 27;354(9193):1851-8. [PubMed: [10584721](#)]
 157. Kaye KS, Stalam M, Shershen WE, Kaye D. Utility of pulse oximetry in diagnosing pneumonia in nursing home residents. *Am J Med Sci*. 2002 Nov;324(5):237-42. [PubMed: [12449443](#)]
 158. Liaqat A, Mason M, Foster BJ, Kulkarni S, Barlas A, Farooq AM, Patak P, Liaqat H, Basso RG, Zaman MS, Pau D. Evidence-Based Mechanical Ventilatory Strategies in ARDS. *J Clin Med*. 2022 Jan 10;11(2) [PMC free article: [PMC8780427](#)] [PubMed: [35054013](#)]
 159. Tang W, Shao X, Chen Q, Zhu L, He Y, Lu E. Nutritional status of protein intake in severe pneumonia patients based on dietary nutrition information system. *J Infect Public Health*. 2021 Jan;14(1):66-70. [PubMed: [31422039](#)]
 160. Ito A, Ishida T, Tokumasu H, Washio Y, Yamazaki A, Ito Y, Tachibana H. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort. *BMC Pulm Med*. 2017 May 02;17(1):78. [PMC free article: [PMC5414343](#)] [PubMed: [28464807](#)]
 161. Mbata G, Chukwuka C, Onyedum C, Onwubere B, Aguwa E. The role of complications of community acquired pneumonia on the outcome of the illness: a prospective observational

- study in a tertiary institution in eastern Nigeria. *Ann Med Health Sci Res.* 2013 Jul;3(3):365-9. [PMC free article: [PMC3793441](#)] [PubMed: [24116315](#)]
162. Hespanhol V, Bárbara C. Pneumonia mortality, comorbidities matter? *Pulmonology.* 2020 May-Jun;26(3):123-129. [PubMed: [31787563](#)]
163. Ruiz LA, España PP, Gómez A, Bilbao A, Jaca C, Arámburu A, Capelastegui A, Restrepo MI, Zalacain R. Age-related differences in management and outcomes in hospitalized healthy and well-functioning bacteremic pneumococcal pneumonia patients: a cohort study. *BMC Geriatr.* 2017 Jun 20;17(1):130. [PMC free article: [PMC5477680](#)] [PubMed: [28633626](#)]
164. Cillóniz C, Ewig S, Polverino E, Marcos MA, Esquinas C, Gabarrús A, Mensa J, Torres A. Microbial aetiology of community-acquired pneumonia and its relation to severity. *Thorax.* 2011 Apr;66(4):340-6. [PubMed: [21257985](#)]
165. Poovieng J, Sakboonyarat B, Nasomsong W. Bacterial etiology and mortality rate in community-acquired pneumonia, healthcare-associated pneumonia and hospital-acquired pneumonia in Thai university hospital. *Sci Rep.* 2022 May 30;12(1):9004. [PMC free article: [PMC9150030](#)] [PubMed: [35637232](#)]
166. Vlaeminck J, Raafat D, Surmann K, Timbermont L, Normann N, Sellman B, van Wamel WJB, Malhotra-Kumar S. Exploring Virulence Factors and Alternative Therapies against *Staphylococcus aureus* Pneumonia. *Toxins (Basel).* 2020 Nov 18;12(11) [PMC free article: [PMC7698915](#)] [PubMed: [33218049](#)]
167. Liao C, Huang X, Wang Q, Yao D, Lu W. Virulence Factors of *Pseudomonas Aeruginosa* and Antivirulence Strategies to Combat Its Drug Resistance. *Front Cell Infect Microbiol.* 2022;12:926758. [PMC free article: [PMC9299443](#)] [PubMed: [35873152](#)]
168. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. *JAMA.* 1996 Jan 10;275(2):134-41. [PubMed: [8531309](#)]
169. Li JS, Hou ZK, Yu XQ, Li SY, Sun ZK, Zhang W, Jia XH, Zheng SP, Wang MH, Wang HF. Prognostic factors for community-acquired pneumonia in middle-aged and elderly patients treated with integrated medicine. *J Tradit Chin Med.* 2012 Jun;32(2):179-86. [PubMed: [22876440](#)]
170. Hoogewerf M, Oosterheert JJ, Hak E, Hoepelman IM, Bonten MJ. Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia. *Clin Microbiol Infect.* 2006 Nov;12(11):1097-104. [PubMed: [17002609](#)]
171. Karakuzu Z, Iscimen R, Akalin H, Kelebek Girgin N, Kahveci F, Sinirtas M. Prognostic Risk Factors in Ventilator-Associated Pneumonia. *Med Sci Monit.* 2018 Mar 05;24:1321-1328. [PMC free article: [PMC5848715](#)] [PubMed: [29503436](#)]
172. Barnes CE, MacIntyre CR. Risk modelling the mortality impact of antimicrobial resistance in secondary pneumococcal pneumonia infections during the 2009 influenza pandemic. *Int J Infect Dis.* 2019 Aug;85:1-6. [PubMed: [31096052](#)]
173. Scott H, Zahra A, Fernandes R, Fries BC, Thode HC, Singer AJ. Bacterial infections and death among patients with Covid-19 versus non Covid-19 patients with pneumonia. *Am J Emerg Med.* 2022 Jan;51:1-5. [PMC free article: [PMC8501886](#)] [PubMed: [34637995](#)]
174. Azuma Y. [Pharmacological studies on rat passive cutaneous anaphylaxis (PCA) (author's transl)]. *Nihon Yakurigaku Zasshi.* 1980 Nov;76(8):685-96. [PubMed: [6168549](#)]
175. Finch RG. Pneumonia: the impact of antibiotic resistance on its management. *Microb Drug Resist.* 1995 Summer;1(2):149-58. [PubMed: [9158749](#)]
176. Chen HH, Stringer A, Eguale T, Rao GG, Ozawa S. Impact of Antibiotic Resistance on Treatment of Pneumococcal Disease in Ethiopia: An Agent-Based Modeling Simulation. *Am J Trop Med Hyg.* 2019 Nov;101(5):1042-1053. [PMC free article: [PMC6838571](#)] [PubMed: [31516111](#)]
177. Hsu JL, Siroka AM, Smith MW, Holodniy M, Meduri GU. One-year outcomes of community-acquired and healthcare-associated pneumonia in the Veterans Affairs

Healthcare System. *Int J Infect Dis.* 2011 Jun;15(6):e382-7. [PMC free article: [PMC3095751](#)] [PubMed: [21393043](#)]

178. Mortensen EM, Kapoor WN, Chang CC, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. *Clin Infect Dis.* 2003 Dec 15;37(12):1617-24. [PubMed: [14689342](#)]
179. Garcia-Vidal C, Ardanuy C, Tubau F, Viasus D, Dorca J, Liñares J, Gudiol F, Carratalà J. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. *Thorax.* 2010 Jan;65(1):77-81. [PubMed: [19996337](#)]
180. Kurahashi K, Kajikawa O, Sawa T, Ohara M, Gropper MA, Frank DW, Martin TR, Wiener-Kronish JP. Pathogenesis of septic shock in *Pseudomonas aeruginosa* pneumonia. *J Clin Invest.* 1999 Sep;104(6):743-50. [PMC free article: [PMC408437](#)] [PubMed: [10491409](#)]
181. Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. *Chemotherapy.* 2005 Aug;51(5):227-33. [PubMed: [16103664](#)]
182. Tsai YF, Ku YH. Necrotizing pneumonia: a rare complication of pneumonia requiring special consideration. *Curr Opin Pulm Med.* 2012 May;18(3):246-52. [PubMed: [22388585](#)]
183. Wallace WA, Fitch PM, Simpson AJ, Howie SE. Inflammation-associated remodelling and fibrosis in the lung - a process and an end point. *Int J Exp Pathol.* 2007 Apr;88(2):103-10. [PMC free article: [PMC2517298](#)] [PubMed: [17408453](#)]
184. McCauley L, Dean N. Pneumonia and empyema: causal, casual or unknown. *J Thorac Dis.* 2015 Jun;7(6):992-8. [PMC free article: [PMC4466426](#)] [PubMed: [26150912](#)]
185. Kastenbauer S, Pfister HW. Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. *Brain.* 2003 May;126(Pt 5):1015-25. [PubMed: [12690042](#)]
186. de Roux A, Cavalcanti M, Marcos MA, Garcia E, Ewig S, Mensa J, Torres A. Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. *Chest.* 2006 May;129(5):1219-25. [PubMed: [16685012](#)]
187. Son M, Jo S, Lee JS, Lee DH. Association between oral health and incidence of pneumonia: a population-based cohort study from Korea. *Sci Rep.* 2020 Jun 12;10(1):9576. [PMC free article: [PMC7293333](#)] [PubMed: [32533077](#)]
188. Rabie T, Curtis V. Handwashing and risk of respiratory infections: a quantitative systematic review. *Trop Med Int Health.* 2006 Mar;11(3):258-67. [PMC free article: [PMC7169664](#)] [PubMed: [16553905](#)]
189. Tessmer A, Welte T, Schmidt-Ott R, Eberle S, Barten G, Suttorp N, Schaberg T., CAPNETZ study group. Influenza vaccination is associated with reduced severity of community-acquired pneumonia. *Eur Respir J.* 2011 Jul;38(1):147-53. [PubMed: [21148226](#)]
190. Ramírez JA. Processes of care for community-acquired pneumonia. *Infect Dis Clin North Am.* 2004 Dec;18(4):843-59. [PMC free article: [PMC7118844](#)] [PubMed: [15555828](#)]
191. Bruns AH, Oosterheert JJ, El Moussaoui R, Opmeer BC, Hoepelman AI, Prins JM. Pneumonia recovery: discrepancies in perspectives of the radiologist, physician and patient. *J Gen Intern Med.* 2010 Mar;25(3):203-6. [PMC free article: [PMC2839328](#)] [PubMed: [19967464](#)]
192. Mittl RL, Schwab RJ, Duchin JS, Goin JE, Albeida SM, Miller WT. Radiographic resolution of community-acquired pneumonia. *Am J Respir Crit Care Med.* 1994 Mar;149(3 Pt 1):630-5. [PubMed: [8118630](#)]
193. Kaye J, Ashline V, Erickson D, Zeiler K, Gavigan D, Gannon L, Wynne P, Cooper J, Kittle W, Sharma K, Morton J. Critical care bug team: a multidisciplinary team approach to reducing ventilator-associated pneumonia. *Am J Infect Control.* 2000 Apr;28(2):197-201. [PubMed: [10760228](#)]
194. Botwright S, Sutawong J, Kingkaew P, Anothaisintawee T, Dabak SV, Suwanpanich C, Promchit N, Kampang R, Isaranuwatthai W. Which interventions for alcohol use should

be included in a universal healthcare benefit package? An umbrella review of targeted interventions to address harmful drinking and dependence. *BMC Public Health*. 2023 Feb 23;23(1):382. [PMC free article: [PMC9948368](#)] [PubMed: 36823618]

195. Hama K, Iwasa Y, Ohara Y, Iwasaki M, Ito K, Nakajima J, Matsushita T, Tohara T, Sakamoto M, Itoda M, Inohara K, Ozaki Y, Sasaki R, Nishi Y, Tsuneishi M, Furuya J, Watanabe Y, Watanabe Y, Sato Y, Yoshida M. Pneumonia incidence and oral health management by dental hygienists in long-term care facilities: A 1-year prospective multicentre cohort study. *Gerodontology*. 2022 Dec;39(4):374-383. [PMC free article: [PMC9787787](#)] [PubMed: 34750855]
196. Viasus D, Vecino-Moreno M, De La Hoz JM, Carratalà J. Antibiotic stewardship in community-acquired pneumonia. *Expert Rev Anti Infect Ther*. 2017 Apr;15(4):351-359. [PubMed: 28002979]
197. Leone R, Moretti U, D'Incau P, Conforti A, Magro L, Lora R, Velo G. Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study. *Drug Saf*. 2013 Apr;36(4):267-76. [PubMed: 23475583]
198. Firman P, Tan KS, Clavarino A, Taing MW, Whitfield K. Pharmacist-Managed Therapeutic Drug Monitoring Programs within Australian Hospital and Health Services-A National Survey of Current Practice. *Pharmacy (Basel)*. 2022 Oct 18;10(5) [PMC free article: [PMC9607166](#)] [PubMed: 36287457]
199. Osti C, Wosti D, Pandey B, Zhao Q. Ventilator-Associated Pneumonia and Role of Nurses in Its Prevention. *JNMA J Nepal Med Assoc*. 2017 Oct-Dec;56(208):461-8. [PubMed: 29453481]
200. Chan SS, Leung DY, Leung AY, Lam C, Hung I, Chu D, Chan CK, Johnston J, Liu SH, Liang R, Lam TH, Yuen KY. A nurse-delivered brief health education intervention to improve pneumococcal vaccination rate among older patients with chronic diseases: a cluster randomized controlled trial. *Int J Nurs Stud*. 2015 Jan;52(1):317-24. [PMC free article: [PMC7094619](#)] [PubMed: 25012957]

Disclosure: Saud Bin Abdul Sattar declares no relevant financial relationships with ineligible companies.

Disclosure: Andrew Nguyen declares no relevant financial relationships with ineligible companies.

Disclosure: Sandeep Sharma declares no relevant financial relationships with ineligible companies.

Copyright © 2024, StatPearls Publishing LLC.

This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.

Bookshelf ID: NBK513321 PMID: [30020693](#)